リコンビナントタンパク質_精製したリコンビナントタンパク質 »
SARS-CoV-2 & COVID-19関連製品

研究者たちは、ウイルスと戦うために診断ツール、治療薬やワクチンなどを日々開発しています。新型コロナウイルスSARS-CoV-2の感染力は非常に強力です。
GenScriptは現在、SARS-CoV-2研究のために必要なツールを提供しています。 COVID-19研究用のすべてのタンパク質は、ELISAおよびウエスタンブロットにおいて優れた抗原として機能します。
オミクロン株関連製品はこちらをご覧ください。
タンパク質
種類 | タンパク質 | 変異部位 | タグ | 製品番号 |
---|---|---|---|---|
20I/501Y.V1, VOC 202012/01, or B.1.1.7 (United Kingdom) (Alpha) |
S1 Protein | N501Y | C-terminal His | Z03526 |
del(69-70) | Z03523 | |||
D614G | Z03507 | |||
P681H | Z03527 | |||
del(69-70)+N439K | Z03524 | |||
del Y144 | Z03522 | |||
A222V | Z03520 | |||
A570D | Z03521 | |||
S-RBD | N501Y | C-terminal Avi & His | Z03533 | |
20H/501Y.V2 or B.1.351 (South Africa) (Beta) |
S1 Protein | N501Y | C-terminal His | Z03526 |
E484K | Z03529 | |||
K417N | Z03530 | |||
E484K+K417N+N501Y | Z03531 | |||
S-RBD | N501Y | C-terminal Avi & His | Z03533 | |
E484K | Z03535 | |||
K417N | Z03536 | |||
E484K+K417N+N501Y | Z03537 | |||
20J/501Y.V3 or P.1 (Brazil) (Gamma) |
S1 Protein | E484K+K417T+N501Y | C-terminal His | Z03602 |
S-RBD | E484K+K417T+N501Y | C-terminal Avi & His | Z03600 | |
20C/S:452R or B.1.429/7 (US, California) (Epsilon) |
S1 Protein | W152C+L452R+D614G | C-terminal His | Z03606 |
S-RBD | L452R | C-terminal Avi & His | Z03603 | |
20A or B.1.617 (India) |
S1 Protein | E484Q+L452R | C-terminal His | Z03609 |
S-RBD | E484Q+L452R | C-terminal Avi & His | Z03607 | |
20A/S:154K or B.1.617.1 (India) (Kappa) |
S1 Protein | T95I+G142D+E154K+L452R+E484Q+D614G+P681R | C-terminal His | Z03611 |
20A/S:478K or B.1.617.2 (India) (Delta) |
S1 Protein | T19R+G142D+del 156-157+R158G+L452R+T478K+D614G+P681R | C-terminal His | Z03612 |
S-RBD | L452R+T478K | C-terminal Avi & His | Z03613 | |
AY.1 or B.1.617.2.1 (India) ("Delta Plus") |
S-RBD | K417N+L452R+T478K | C-terminal Avi & His | Z03689 |
20A or B.1.617.3 (India) |
S1 Protein | T19R+G142D+L452R+E484Q+D614G+P681R | C-terminal His | Z03615 |
C.37 (Peru) (Lambda) |
S1 Protein | G75V+T76I+del 247-253+L452Q+F490S | C-terminal His | Z03698 |
S-RBD | L452Q+F490S | C-terminal Avi & His | Z03696 | |
B.1.1.207 (Nigeria) |
S1 Protein | Q52R+del(69-70)+E484K+ Q677H+D614G | C-terminal His | Z03604 |
Other | S1 Protein | N439K | C-terminal His | Z03525 |
Y453F | Z03528 | |||
S-RBD | N439K | C-terminal Avi & His | Z03532 | |
Y453F | Z03534 |
タンパク質 | タグ | 由来 | 製品番号 | 製品名 |
---|---|---|---|---|
N protein | tag-free | E.coli | Z03488 | SARS-CoV-2 Nucleocapsid protein |
His | E.coli | Z03480 | SARS-CoV-2 Nucleocapsid protein (His Tag) | |
S-ECD | His&Flag | Sf9 insect cells | Z03481 | SARS-CoV-2 Spike protein (ECD, His & Flag Tag) |
S-RBD | His | Sf9 insect cells | Z03479 | SARS-CoV-2 Spike protein (RBD, His Tag) |
CHO | Z03514 | SARS-CoV-2 Spike protein (RBD, His Tag, CHO-expressed) | ||
Avi&His | Human Cells | Z03483 | SARS-CoV-2 Spike protein (RBD, His & Avi Tag) | |
CHO | Z03512 | SARS-CoV-2 Spike protein (RBD, His & Avi Tag, CHO-expressed) | ||
Fc | Human Cells | Z03491 | SARS-CoV-2 Spike protein (RBD, mFc Tag) | |
CHO | Z03513 | SARS-CoV-2 Spike protein (RBD, mFc Tag, CHO-expressed) | ||
S1 protein | tag-free | Human Cells | Z03501 | SARS-CoV-2 Spike protein (S1) |
His | Human Cells | Z03485 | SARS-CoV-2 Spike protein (S1, His Tag) | |
CHO | Z03515 | SARS-CoV-2 Spike protein (S1, His Tag, CHO-expressed) | ||
N & S-RBD Fusion | His | HEK293 | Z03505 | SARS-CoV-2 Nucleocapsid S-RBD Fusion (His Tag) |
ACE-2 | Fc | CHO | Z03516 | ACE-2 Fc Chimera, Human (CHO-expressed) |
S-RBD HRP(野生型)は、SARS-CoV-2サロゲートウイルス中和試験(sVNT)キット(カタログ番号L00847-A)のコンポーネントの1つです。
キットの代替品としてS-RBD HRP(バリアント)をお勧めします。ユーザーは、バリアントsVNTアッセイを変更および最適化できます。
種類 | タンパク質 | 変異部位 | タグ | ラベル | 適応 | 製品番号 |
---|---|---|---|---|---|---|
Wild type | S-RBD | / | C-terminal Avi & His | HRP | ELISA 1:1000 | Z03594 |
United Kingdom B.1.1.7 Alpha |
N501Y | C-terminal Avi & His | ELISA 1:1000 | Z03595 | ||
South Africa B.1.351 Beta |
E484K+K417N+N501Y | C-terminal Avi & His | ELISA 1:1000 | Z03596 | ||
Brazil P.1 Gamma |
E484K+K417T+N501Y | C-terminal Avi & His | ELISA 1:1000 | Z03601 | ||
US, California B.1.429/7 Epsilon |
L452R | C-terminal Avi & His | ELISA 1:1000 | Z03605 | ||
India B.1.617 | E484Q+L452R | C-terminal Avi & His | ELISA 1:1000 | Z03608 | ||
India B.1.617.2 Delta |
L452R+T478K | C-terminal Avi & His | ELISA 1:1000 | Z03614 | ||
AY.1 or B.1.617.2.1 (India) ("Delta Plus") |
K417N+L452R+T478K | C-terminal Avi & His | ELISA 1:1000 | Z03690 | ||
C.37 (Peru) (Lambda) |
L452Q+F490S | C-terminal Avi & His | ELISA 1:1000 | Z03697 |
抗体
製品番号 | 詳細 | タイプ | Clone ID | 推奨適応 | 推奨する組み合わせ (キャプチャ-検出) |
---|---|---|---|---|---|
A02087 | Neutralizing Antibody Standard Hot! | - | - | Calibrate quantitative assay of SARS-CoV-2 neutralizing antibody (sVNT, PRNT, pVNT) | - |
A02038 | Control antibody | Chimeric mAb, IgG | HC2001 | ELISA | - |
A02046 | Chimeric mAb, IgM | hIgM2001 | ELISA | - | |
A02071 | Chimeric mAb, IgA | hIgA2001 | ELISA | - | |
A02133 | Humanized mAb, IgG | S9HC (ADE-Causing) | ELISA | - | |
A02088 | Neutralizing Antibody | Chimeric mAb, IgM | R323IgM | ELISA | - |
A02109 | Humanized mAb, IgG | COV2109 (E484 specific) | ELISA | - | |
A02110 | COV2110 (N501 specific) | ELISA | - | ||
A02140 | Rabbit mAb | 21F1 (417N specific) |
ELISA, Neu | - | |
A02051 | BS-R2B2 | ELISA, FACS, Neu | A02058-A02051 | ||
A02052 | BS-R2B17 | ELISA, FACS, Neu | - | ||
A02053 | 4G6 | ELISA, FACS, WB, Neu | - | ||
A02054 | 12D3 | ELISA, FACS, Neu | - | ||
A02055 | Mouse mAb | 6D11F2 | ELISA, FACS, Neu | - | |
A02056 | 5B7D7 | ELISA, FACS, Neu | - | ||
A02057 | BS-M0220 | ELISA, Neu | - | ||
A02058 | Antibody Pairs | Rabbit mAb | BS-R2B12 | ELISA, FACS | A02058-A02051 |
製品番号 | 詳細 | タイプ | Clone ID | 推奨適応 | 推奨する組み合わせ (キャプチャ-検出) |
---|---|---|---|---|---|
A02039 | Control Antibody | Chimeric mAb, IgG | HC2003 | ELISA | - |
A02059 | Chimeric mAb, IgM | hlgM2003 | ELISA | - | |
A02090 | Chimeric mAb, IgA | N22IgA | ELISA | - | |
A02047 | Antibody Pairs | Mouse mAb | 3H11 | ELISA, WB | A02047-A02048 |
A02048 | 4H2 | ELISA, WB | A02047-A02048 A02049-A02048 |
||
A02049 | 3F9 | ELISA, WB | A02049-A02048 A02050-A02049 |
||
A02050 | 23F2 | ELISA, WB | A02050-A02049 | ||
A02135 | N338 | ELISA/CLIA, WB, LFA | A02135-A02136 Hot! |
||
A02135-A02138 | |||||
A02136 | Rabbit mAb | N34 | ELISA/CLIA, WB, LFA | A02135-A02136 Hot! |
|
A02138 | Cocktail | - | ELISA/CLIA, WB, LFA | A02135-A02138 | |
A02137 | Detection Antibody | Rabbit mAb | N66 | ELISA/CLIA, WB | - |
カタログ
|
商品
|
---|---|
A01854-200
|
Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb - 200 μl |
A01428-100
|
THE™ DYKDDDDK Tag Antibody [HRP], mAb, Mouse - 100 μg |
A00612
|
THE™ His Tag Antibody [HRP], mAb, Mouse - 100 μg |
M00091
|
Streptavidin-HRP - 1 mg |
検出キット
製品番号 | 製品名 |
---|---|
* L00847 | SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit |
L00846 | SARS-CoV-2 NP&RBD Total Antibody ELISA Kit |
ペプチドプール
Cat. No. | Product Name |
---|---|
RP30025
|
SARS-CoV-2 Spike Glycoprotein D614G - 2 vials(25µg/peptide) |
RP30026
|
SARS-CoV-2 Spike Glycoprotein RBD N501Y - 1 vial(25µg/peptide) |
RP30010
|
HCoV-229E Spike Glycoprotein - 2 vials(25µg/peptide) |
RP30011
|
HCoV-OC43 Spike glycoprotein - 2 vials(25µg/peptide) |
RP30020
|
SARS-CoV-2 Spike Glycoprotein-crude - 2 vials(25µg/peptide) |
RP30027
|
SARS-CoV-2 Spike Glycoprotein-90% purity - 2 vials(25µg/peptide) |
RP30012
|
SARS-CoV-2 ORF3a - 1 vial(25µg/peptide) |
RP30014
|
SARS-CoV-2 ORF6 - 1 vial(25µg/peptide) |
RP30016
|
SARS-CoV-2 ORF7a - 1 vial(25µg/peptide) |
RP30015
|
SARS-CoV-2 ORF7b - 1 vial(25µg/peptide) |
RP30017
|
SARS-CoV-2 ORF8 - 1 vial(25µg/peptide) |
RP30019
|
SARS-CoV-2 ORF9B - 1 vial(25µg/peptide) |
RP30018
|
SARS-CoV-2 ORF10 - 1 vial(25µg/peptide) |
RP30021
|
SARS-CoV-2 E - 1 vial(25µg/peptide) |
RP30022
|
SARS-CoV-2 M - 1 vial(25µg/peptide) |
RP30013
|
SARS-CoV-2 N - 1 vial(25µg/peptide) |
RP30023
|
SARS-CoV-2 Y14 - 1 vial(25µg/peptide) |
安定発現株
発現タンパク質 | セルライン | 製品番号 |
---|---|---|
ACE2 | HEK293/ACE2 | M00770 |
ACE2 | CHO-K1/ACE2 | M00771 |
SARS-CoV-2 Spike protein | CHO-K1/Spike Stable Cell Line | M00803 |
SARS-CoV-2 Spike protein | HEK293T/Spike Stable Cell Line | M00804 |
ウェビナー
-
COVID-19 - mechanism, infection rate and tools for monitoring
-
Pathways for treating and eradicating COVID-19 with solutions to minimize time to results